Earlier this year, the American Association of Cancer Research (AACR) partnered with Novocure, a global oncology company, to launch several new funding initiatives to support innovative research focused on Tumor Treating Fields (TTFields). TTFields...
The Centers for Medicare & Medicaid Services offers value-based programs that “reward health care providers with incentive payments for the quality of care they give to people.” Many private insurers offer similar payment approaches...
The FDA has approved a molecularly targeted therapeutic for treating certain adults with a rare blood cancer called myelofibrosis.
There has been an explosion in the number of cancer therapeutics and clinical trials in the recent past, owing to our ability to better define the molecular targets of different cancers using cutting-edge technologies....
The molecularly targeted therapeutic entrectinib is the second therapeutic of its kind approved by the FDA for use based on tumor biomarker rather than the site where the cancer originated. The U.S. Food and...
The FDA approved the molecularly targeted therapeutic entrectinib to treat certain patients with metastatic non–small cell lung cancer. Learn more.
KRAS has been difficult to target, but some research presented at the Molecular Targets and Therapeutics conference suggested that may be changing.
A molecularly targeted therapeutic has been approved by the FDA for the treatment of tenosynovial giant cell tumors. Learn more.
The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held this year at the Hynes Convention Center in Boston Oct. 26-30, has once again brought together members of academia, pharmaceutical industry, federal regulatory agencies, and all other stakeholders in the cancer drug development space from across the globe to discuss the most up-to-date advances.
The FDA approved pembrolizumab, in immunotherapy called a checkpoint inhibitor, to treat certain patients with esophageal cancer.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More